Literature DB >> 16788800

Comment on: Evans JM, Ogston SA, Emslie-Smith A, Morris A (2006) risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.

J A Johnson, S H Simpson, D T Eurich, S R Majumdar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788800     DOI: 10.1007/s00125-006-0323-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  7 in total

Review 1.  Is metformin cardioprotective?

Authors:  Afshin Sasali; Jack L Leahy
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

2.  Do sulfonylurea drugs increase the risk of cardiac events?

Authors:  David S H Bell
Journal:  CMAJ       Date:  2006-01-17       Impact factor: 8.262

3.  Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.

Authors:  Scot H Simpson; Sumit R Majumdar; Ross T Tsuyuki; Dean T Eurich; Jeffrey A Johnson
Journal:  CMAJ       Date:  2006-01-17       Impact factor: 8.262

4.  Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.

Authors:  J A Johnson; S H Simpson; E L Toth; S R Majumdar
Journal:  Diabet Med       Date:  2005-04       Impact factor: 4.359

5.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Authors:  Jeffrey A Johnson; Sumit R Majumdar; Scot H Simpson; Ellen L Toth
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

6.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

7.  Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.

Authors:  J M M Evans; S A Ogston; A Emslie-Smith; A D Morris
Journal:  Diabetologia       Date:  2006-03-09       Impact factor: 10.122

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.